Ketamine Co-induction for Patients With Major Depressive Disorder

Ketamine Co-induction for Patients With Major Depressive Disorder; a Randomized Clinical Trial

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03666494

Enrollment

Registered

2018-09-11

Start date

2018-12-31

Completion date

2019-12-31

Last updated

2018-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Depression, Ketamine

Brief summary

Ketamine hydrochloride, an anesthetic medication, has been demonstrated to acutely and rapidly improve depressive symptoms but not yet been adequately studied for this effect when used as part of a general anesthetic for surgery. This proposed single-centre, double-blinded, randomized clinical trial of adult patients with depression presenting for gynecologic surgery would compare severity of depressive symptoms between patients receiving and not receiving ketamine as part of their general anesthetic.

Interventions

DRUGKetamine Hydrochloride

As part of anesthetic induction, the addition of ketamine hydrochloride 0.5mg/kg.

DRUGPropofol

As part of the patient's anesthetic induction, they will receive propofol.

DRUGFentanyl

As part of the patient's anesthetic induction, they will receive fentanyl.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of major depressive disorder * Presentation for gynecologic surgery requiring a general anesthetic

Exclusion criteria

* Marked co-morbid cardiovascular disease * Marked co-morbid respiratory disease * History of intracranial hypertension * History of seizures * ASA Physical Status Classification IV or greater * History of psychosis * Current pregnancy * Contraindication to ketamine administration

Design outcomes

Primary

Measure	Time frame	Description
Depression Severity	At time of discharge from post-anesthetic care unit, until 3 hours post operatvie	Severity of depression as measured by Montgomery-Asberg Depression Rating Scale (MADRS), 0-60 where 0 to 6 is normal, 7-19 is mild depression, 20-34 is moderate depression, and \>34 is severe depression.

Secondary

Measure	Time frame	Description
Pain Score	Pre-operatively	Verbally reported numeric pain score (out of 10)
Analgesia use	Pre-operatively	Morphine equivalents (in milligrams)

Contacts

Primary ContactJonathan Gamble, MD

j_gamble@yahoo.com306-655-1183

Backup ContactJordon Steeg, MD

jordon.steeg@usask.ca306-222-9782

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026